February 28, 2022 News by Marisa Wexler, MS #ACTRIMS2022 ā In New Mouse Model, Evobrutinib Shows Efficacy Researchers developed a new mouse model that more closely captures a specific type of inflammation characteristic of progressive multiple sclerosis (MS) ā and found, in experiments, that treatment with an oral medicationĀ called evobrutinibĀ can lessen disease activity. This new mouse model may help scientists in MS to better study…
November 19, 2020 News by Patricia Inacio, PhD Progressive MS Focus of EMSP Virtual Meeting Open to All Starting Today Progressive multiple sclerosis (MS) is the focus of the 2020 virtualĀ European Multiple Sclerosis Platform (EMSP)Ā annual meeting that runs though Friday, Nov. 20. Registration is free for the two-dayĀ conference. Those interested in participating can registerĀ here. According to a EMSP press release, topics to be discussed include the most…
July 11, 2016 News by Patricia Silva, PhD Workings of Common Statin, Simvastatin, Explored in Ways Relevant to Multiple Sclerosis One of the worldās most commonly used medications ā the cholesterol-lowering drug simvastatin ā was found to affect the immune system in a way that can be explored to treat inflammatory diseases such as multiple sclerosis (MS). Researchers have earlier noted that simvastatin, a cholesterol-lowering drug, is beneficial for MS…
June 15, 2015 News by Patricia Silva, PhD MediciNova Announces Update On Phase 2b Trial of MN-166 (Ibudilast) Involving 255 Progressive MS Patients MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the ongoing clinical trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS) has finished the randomization of 255 patients, exceeding the…
May 25, 2015 News by Maureen Newman New Compound Tested in Lab Shows Promise for Progressive Multiple Sclerosis Exploratory research conducted at Virginia Commonwealth University and the University of Illinois at Chicago may translate into a new therapeutic agent to treat progressive multiple sclerosis. Researchers in the laboratories of Dr. Jefferey L. Dupree and Dr. Douglas L. Feinstein tested a new compound in mice with induced multiple sclerosis…
May 13, 2015 News by Patricia Silva, PhD Major Progressive MS Trial Completes Enrollment For Experimental Therapy While multiple sclerosis (MS) is consideredĀ a rare condition with majorĀ unmet medical needs, the treatments for progressive forms of MS are evenĀ scarcer, with no viable, FDA-approved drugs available to specifically addressĀ these forms of the disease. Because of this, the MS community is eagerly followingĀ a major…
May 8, 2015 News by Patricia Silva, PhD MediciNova Completes Enrollment for Phase 2b Study of Experimental Progressive Multiple Sclerosis Treatment MediciNova, Inc., a publicly-traded biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the National Institute of Neurological Disorders and Stroke (NINDS) notified the company of full enrollment of theirĀ ongoing clinical study evaluating ibudilastĀ (MN-166) for the treatment of progressive…
April 23, 2015 News by admin Phase III Study of Experimental MS Therapy Meets Primary Endpoint, Results to be Presented at ANN Meeting MedDay, a French biotechnology company that studies treatments for nervous system disorders, including multiple sclerosis, announced that MD1003, a highly-concentrated biotin, is effective forĀ treatment of progressive multiple sclerosis, according to results from a recent Phase III trial. MD1003 may have two beneficial effects: 1) increasing myelin, the fatty nerve-insulating…
April 22, 2015 News by Maureen Newman Progressive MS Pipeline Slowly Filling With New, Experimental Therapies As the most common non-traumatic cause of disability in young people in the industrialized world, multiple sclerosis affects more than 2.5 million people globally. Those who suffer with the diseaseĀ are categorized into two types of multiple sclerosis patients: those with relapsing-remitting multiple sclerosis (RRMS) make up the majority of patients…
April 16, 2015 News by admin Co-existing MS and FM Influences Pain Threshold, According to New Study People with multiple sclerosis (MS) commonly experience a low pain threshold and sensitivity to heat and cold. If a person has multiple sclerosis along with fibromyalgia (FM), that could make this sensitivity even more intense. Until now, no group has studied this phenomenon. In a study titled “…
April 10, 2015 News by Patricia Silva, PhD MedDay To Release Phase III Clinical Trial Results for Experimental Progressive Multiple Sclerosis Therapy MedDayĀ recently announced in a news releaseĀ that it is preparing to release the design and results of its clinical trial to assess the safety and efficacy of MD1003 in primary and secondary progressive multiple sclerosis (MS) treatment. Data on the Phase III clinical trial (MS-SPI) will be presented…
December 4, 2014 News by Patricia Silva, PhD GeNeuro and Servier to Co-Develop Breakthrough Multiple Sclerosis Drug Neurology and autoimmune therapeutics companyĀ GeNeuro SA has just announced the formation of a partnership with independent French pharmaceutical companyĀ ServierĀ for the co-development and marketing of GNbAC1 for Multiple Sclerosis (MS). It is the first humanized monocloncal antibody treatment formulated to address one of this disease’s causal factors, making it…
October 3, 2014 News by Patricia Silva, PhD National MS Society Pledges $19 Million Dollars to Fund 54 New Studies 54 new multiple sclerosis (MS)Ā research and development initiatives are set to receive substantial funding in order to accelerate new therapies. The National Multiple Sclerosis Society (NMSS) announced that it has pledged $19 million to fund these new MS studies as part of their mission to better manage…
October 1, 2014 News by Patricia Silva, PhD Glialogix Drug for Progressive MS Funded by National Multiple Sclerosis Society San Francisco Bay Area-based Glialogix, Inc., a biopharmaceutical company that specializes in developing novel treatments for multiple sclerosis (MS), announced yesterday that they have closed aĀ Sponsored Research Agreement with Fast Forward, a non-profit organizationĀ that aims to accelerate MS treatment development.Ā Glialogix will receive funding for one of their…
September 24, 2014 News by Patricia Silva, PhD Multiple Sclerosis Summit in Quebec to Feature “Deepelling” As Encouragement for Active MS Lifestyles Deepelling International conferences on multiple sclerosis (MS) typically gather the most accomplished experts and leading biotech companies under one roof to exchange discoveries and celebrate new hope for MS patients all over the world. Quebec is one of North America’s epicenters for MS research and developments. This year, on…
September 17, 2014 News by Charles Moore $31.4 Million in Funding Earmarked For Progressive Multiple Sclerosis Research The first round of 22 research grants have been awarded to projects in nine countries by the International Progressive MS Alliance, with the goal of removing barriers to developing treatments for progressive MS. The 22 projects were chosen from 195 research proposals submitted by researchers in 22 countries and…